{
    "clinical_study": {
        "@rank": "35002", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "Enbrel, LBEC0101"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "LBEC0101, Enbrel"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the pharmacokinetic characteristic of LBEC0101 25mg with active comparator,\n      Enbrel\u00ae 25mg."
        }, 
        "brief_title": "Study to Compare the Safery and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel\u00ae", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males, 20 to 45 years of age the moment of screening\n\n          -  Body mass index is between 18.0 and 30.0 kg/m\n\n        Exclusion Criteria:\n\n          -  The tuberculosis patient of latent tuberculosis patient\n\n          -  Hypersensitivity response to the test and comparator drugs"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "firstreceived_date": "November 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01725620", 
            "org_study_id": "LG-ECCL003"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2"
                ], 
                "intervention_name": "LBEC0101 (Etanercept 25mg)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group 1", 
                    "Group 2"
                ], 
                "intervention_name": "Enbrel (Etanercept 25mg)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "TNFR-Fc fusion protein"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seoul National University Hospital, Clinical Trial Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Single-dosing, 2-way Cross-over Study to Compate the Safety and Pharmacokinetic Characteristics of LBEC0101(Etanercept) 25mg With Those of Enbrel\u00ae 25mg After Subcutaneous Injection in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Seoul National University College of Medicine and Hospitaal", 
            "last_name": "Kyung-Sang Yu, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01725620"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "LG Life Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LG Life Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}